In Vitro Diagnostics (IVD) Market Size, Share, Report 2024-2033
The global in vitro diagnostics (IVD) market size was estimated at around USD 77.96 billion in 2023 and it is projected to hit around USD 120.49 billion by 2033, growing at a CAGR of 4.45% from 2024 to 2033. The in vitro diagnostics (IVD) market is driven by the rising incidence of chronic diseases, rise of personalized medicine, point-of-care testing (POCT) growth, and global expansion and market opportunities.
The in vitro diagnostics (IVD) market plays a pivotal role in the healthcare sector, providing essential diagnostic information for disease detection, monitoring, and treatment decision-making. As a rapidly evolving segment of the healthcare industry, IVD encompasses a diverse range of tests and diagnostic tools conducted outside the human body.
The growth of the in vitro diagnostics (IVD) market is propelled by various factors that collectively contribute to its expanding significance in the healthcare sector. One primary driver is the increasing prevalence of chronic diseases globally, necessitating efficient diagnostic tools for early detection and monitoring. Additionally, the aging population contributes to the growing demand for diagnostic tests, as elderly individuals often require regular health assessments. Technological advancements, such as the integration of molecular diagnostics and next-generation sequencing, further enhance the precision and scope of diagnostic capabilities, fostering market growth. The rise of personalized medicine, tailoring treatments based on genetic profiles, has spurred demand for IVD tests that provide more nuanced insights into individual health conditions.
The reagents segment secured the majority share, accounting for 66% of the total revenue in 2023. It is expected to maintain its dominance, experiencing the fastest CAGR from 2024 to 2033. This sustained growth can be attributed to the extensive research and development initiatives undertaken by major industry players, aiming to create innovative reagents and test kits. An illustrative example is BD's achievement in February 2023, gaining market approval for the BD Onclarity HPV Assay to be used in conjunction with the ThinPrep Pap Test in the U.S. The heightened focus on Research and Development (R&D) endeavors, specifically geared towards faster cancer detection and precision medicine, is enabling companies to carve out profitable niches within the in vitro diagnostics (IVD) sector.
The rise of precision medicine is anticipated to fuel the demand for these innovative reagents and consumables. Meanwhile, the instruments segment secured the second-largest share in 2023. Anticipated growth in this segment is driven by increasing approvals for novel IVD instruments. For example, in April 2023, bioMérieux SA submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for VITEK REVEAL, a rapid Antimicrobial Susceptibility Testing (AST) system. Companies are aligning their instrument launches with the global surge in demand for genetic testing.
In 2023, the immunoassay segment emerged as the leader in revenue generation. The heightened occurrence of chronic and communicable diseases, coupled with a growing emphasis on early diagnosis, contributed to an escalated demand for immunological methods. This includes various forms of Enzyme-Linked Immunosorbent Assays (ELISAs). Notably, major industry players are directing their efforts towards Research and Development (R&D) initiatives focused on the creation of new immunological diagnostic instruments and tests for in vitro diagnostics (IVD) applications. As an illustration, in October 2023, Sysmex Corporation and Fujirebio Holdings, Inc. joined forces to bolster their R&D, production, clinical development, and marketing activities in the field of immunoassay.
Concurrently, the coagulation segment is projected to exhibit the most rapid CAGR from 2024 to 2033. This growth is attributed to the increasing prevalence of cardiovascular diseases, blood-related disorders, and autoimmune diseases. Advancements in instruments, including the introduction of updated handheld coagulation analyzers like the Xprecia Stride Coagulation Analyzer, are anticipated to augment the overall workflow of detection. Key players in the provision of instruments and coagulation tests include Abbott, Siemens Healthcare GmbH, and Beckman Coulter, Inc.
The hospitals segment dominated the revenue share in 2023, primarily driven by an increase in hospitalizations requiring swift diagnostic support. The continual development of healthcare infrastructure, coupled with favorable initiatives from government bodies, is expected to augment existing hospital facilities, leading to a surge in demand for hospital-based in vitro diagnostics (IVD) tests. Given that a substantial volume of IVD devices is procured by hospitals and utilized in significant quantities, the demand is particularly noteworthy.
In December 2023, the American Hospital Association communicated to the FDA, urging against the application of device regulations on hospital's Laboratory Developed Tests (LDTs). On the other hand, the homecare segment is poised for a high CAGR from 2024 to 2033, fueled by the growing geriatric population and an increased demand for in vitro diagnostics (IVD) devices in home care settings. This is accompanied by a rising need for innovative molecular diagnostic and immunoassay platforms, facilitating patients in conducting self-tests.
In 2023, the infectious diseases segment emerged as the dominant force in the market, with a significant boost attributed to the outbreak of the COVID-19 pandemic in recent years. This surge in segment share was further propelled by key players introducing novel testing products aimed at enhancing access to high-quality and innovative laboratory services for both patients and healthcare providers. An illustrative example is BD's achievement in February 2023, obtaining Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test designed to detect SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV). Initiatives of this nature by key industry players are poised to play a pivotal role in driving market growth.
Conversely, the oncology segment is anticipated to exhibit the fastest CAGR from 2024 to 2033. The increasing incidence of cancer, coupled with a high mortality rate, is driving the demand for cancer biomarker tests at an early stage. Furthermore, the industry is expected to witness growth due to the rising approvals of novel tests, ongoing Research and Development (R&D) activities, and favorable initiatives undertaken by regulatory bodies. For instance, in June 2023, the U.S. FDA announced a pilot program providing manufacturers with the opportunity to submit validation and performance data for Laboratory Developed Tests (LDTs) for cancer. Additionally, in April 2023, Biocartis Group NV and APIS Assay Technologies Ltd. collaborated to manufacture and commercialize a breast cancer subtyping test on Idylla, a molecular diagnostics platform
In 2023, North America asserted its dominance in the market, capturing a substantial share of 43%. Projections indicate that the region will maintain its leading position throughout the forecast period. Several factors contribute to the collective drive of the market in North America, including the increasing prevalence of chronic diseases, the presence of robust industry players, a growing number of novel test launches, and supportive government funding. An illustrative example is the January 2023 collaboration between BD and CerTest Biotec, securing Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a Polymerase Chain Reaction (PCR) test designed for Mpox virus detection in the U.S.
In contrast, Asia Pacific is poised for substantial growth from 2024 to 2033. This anticipated growth in the regional market can be attributed to several factors, including the presence of stabilizing economies, a rapidly expanding middle-class population, supportive government policies, and swift urbanization across the region. A notable collaboration in October 2023 involved Fapon and Halodoc partnering to boost in vitro diagnostic product sales and services in Indonesia.
By Product
By Technology
By Application
By Test Location
By End-use
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on In Vitro Diagnostics (IVD) Market
5.1. COVID-19 Landscape: In Vitro Diagnostics (IVD) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global In Vitro Diagnostics (IVD) Market, By Product
8.1. In Vitro Diagnostics (IVD) Market, by Product, 2024-2033
8.1.1. Instruments
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Reagents
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global In Vitro Diagnostics (IVD) Market, By Technology
9.1. In Vitro Diagnostics (IVD) Market, by Technology, 2024-2033
9.1.1. Immunoassay
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Hematology
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Clinical Chemistry
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Molecular Diagnostics
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Coagulation
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Microbiology
9.1.6.1. Market Revenue and Forecast (2021-2033)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global In Vitro Diagnostics (IVD) Market, By Application
10.1. In Vitro Diagnostics (IVD) Market, by Application, 2024-2033
10.1.1. Infectious Diseases
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Diabetes
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Oncology
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Cardiology
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Nephrology
10.1.5.1. Market Revenue and Forecast (2021-2033)
10.1.6. Autoimmune Diseases
10.1.6.1. Market Revenue and Forecast (2021-2033)
10.1.7. Drug Testing
10.1.7.1. Market Revenue and Forecast (2021-2033)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global In Vitro Diagnostics (IVD) Market, By Test Location
11.1. In Vitro Diagnostics (IVD) Market, by Test Location, 2024-2033
11.1.1. Point of Care
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Home-care
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global In Vitro Diagnostics (IVD) Market, By End-use
12.1. In Vitro Diagnostics (IVD) Market, by End-use, 2024-2033
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. Laboratory
12.1.2.1. Market Revenue and Forecast (2021-2033)
12.1.3. Home-care
12.1.3.1. Market Revenue and Forecast (2021-2033)
12.1.4. Others
12.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 13. Global In Vitro Diagnostics (IVD) Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.2. Market Revenue and Forecast, by Technology (2021-2033)
13.1.3. Market Revenue and Forecast, by Application (2021-2033)
13.1.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.1.5. Market Revenue and Forecast, by End-use (2021-2033)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.6.2. Market Revenue and Forecast, by Technology (2021-2033)
13.1.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.1.6.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.1.7. Market Revenue and Forecast, by End-use (2021-2033)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.8.2. Market Revenue and Forecast, by Technology (2021-2033)
13.1.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.1.8.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.1.8.5. Market Revenue and Forecast, by End-use (2021-2033)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.2. Market Revenue and Forecast, by Technology (2021-2033)
13.2.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.2.5. Market Revenue and Forecast, by End-use (2021-2033)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.6.2. Market Revenue and Forecast, by Technology (2021-2033)
13.2.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.7. Market Revenue and Forecast, by Test Location (2021-2033)
13.2.8. Market Revenue and Forecast, by End-use (2021-2033)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.9.2. Market Revenue and Forecast, by Technology (2021-2033)
13.2.9.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.10. Market Revenue and Forecast, by Test Location (2021-2033)
13.2.11. Market Revenue and Forecast, by End-use (2021-2033)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.12.2. Market Revenue and Forecast, by Technology (2021-2033)
13.2.12.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.12.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.2.13. Market Revenue and Forecast, by End-use (2021-2033)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.14.2. Market Revenue and Forecast, by Technology (2021-2033)
13.2.14.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.14.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.2.15. Market Revenue and Forecast, by End-use (2021-2033)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.2. Market Revenue and Forecast, by Technology (2021-2033)
13.3.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.3.5. Market Revenue and Forecast, by End-use (2021-2033)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.6.2. Market Revenue and Forecast, by Technology (2021-2033)
13.3.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.6.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.3.7. Market Revenue and Forecast, by End-use (2021-2033)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.8.2. Market Revenue and Forecast, by Technology (2021-2033)
13.3.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.8.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.3.9. Market Revenue and Forecast, by End-use (2021-2033)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.10.2. Market Revenue and Forecast, by Technology (2021-2033)
13.3.10.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.10.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.3.10.5. Market Revenue and Forecast, by End-use (2021-2033)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.11.2. Market Revenue and Forecast, by Technology (2021-2033)
13.3.11.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.11.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.3.11.5. Market Revenue and Forecast, by End-use (2021-2033)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.2. Market Revenue and Forecast, by Technology (2021-2033)
13.4.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.4.5. Market Revenue and Forecast, by End-use (2021-2033)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.6.2. Market Revenue and Forecast, by Technology (2021-2033)
13.4.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.6.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.4.7. Market Revenue and Forecast, by End-use (2021-2033)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.8.2. Market Revenue and Forecast, by Technology (2021-2033)
13.4.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.8.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.4.9. Market Revenue and Forecast, by End-use (2021-2033)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.10.2. Market Revenue and Forecast, by Technology (2021-2033)
13.4.10.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.10.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.4.10.5. Market Revenue and Forecast, by End-use (2021-2033)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.11.2. Market Revenue and Forecast, by Technology (2021-2033)
13.4.11.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.11.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.4.11.5. Market Revenue and Forecast, by End-use (2021-2033)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.2. Market Revenue and Forecast, by Technology (2021-2033)
13.5.3. Market Revenue and Forecast, by Application (2021-2033)
13.5.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.5.5. Market Revenue and Forecast, by End-use (2021-2033)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.6.2. Market Revenue and Forecast, by Technology (2021-2033)
13.5.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.5.6.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.5.7. Market Revenue and Forecast, by End-use (2021-2033)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.8.2. Market Revenue and Forecast, by Technology (2021-2033)
13.5.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.5.8.4. Market Revenue and Forecast, by Test Location (2021-2033)
13.5.8.5. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 14. Company Profiles
14.1. Abbott
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. bioMérieux SA
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. QuidelOrtho Corporation
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Siemens Healthineers AG
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Bio-Rad Laboratories, Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Qiagen
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Sysmex Corporation
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Charles River Laboratories
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Quest Diagnostics Incorporated
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Agilent Technologies, Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers